ClinicalTrials.gg
TerminatedNCT04436523Updated Feb 20, 2026Results posted

Blood Flow Restriction After Meniscus Repair

An interventional study of Blood flow restriction (Delfi Personalized Tourniquet System) and Standard rehabilitation in Meniscus Disorder, Meniscus, Torn Tibial and Meniscus Lesion, sponsored by University of California, San Francisco. Terminated at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment

Why this study was terminated
We had difficulty with enrolling enough participants. We looked to include patients undergoing isolated meniscus repair surgery doing PT with our group and this group proved to be too small to enroll enough patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 115 studies in Muscular Atrophy with a site in United States — 15 open to participants now, 26 under way, 2 of them phase 3. Muscular Atrophy · United States.

Enrollment
86th of 105
15 · median 40
Started
2020
with 9 others
No phase
57 of 115
8 open now
Registered
72nd of 115
by date

Among the 115 studies in Muscular Atrophy with a site in United States, this one is the 86th largest by enrollment of the 105 interventional ones that give a count, is one of 10 that started in 2020, is one of 57 with no phase, and was the 72nd registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 77 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

15 of the 115 studies in Muscular Atrophy with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 52 Muscular Atrophy studies recruiting now, 25 (48%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Muscular Atrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate post-operative outcomes after meniscus surgery in participants undergoing blood flow restriction training as a rehabilitative adjunct compared to those with standard rehabilitation.

Read the detailed description

The investigators will conduct a double-blinded, single-institution, randomized controlled trial to compare patients undergoing arthroscopic meniscus repair with post-operative rehabilitation protocol as (1) a standard-of-care rehabilitative protocol with a non-occlusive blood pressure cuff (inflated to 20-30 mm Hg) applied to the operative extremity versus (2) blood flow restriction training with cuff occlusion applied to the operative extremity. Patients will be enrolled prospectively and pre-operatively at their initial clinic visit after meniscus injury.

Rehabilitative exercises would be advanced per the physical therapists' discretion with similar exercises for patients in both groups for direct comparison. These exercises are part of an already-established post-operative protocol that is in place, with the only difference being the addition of the blood flow restriction protocol in the intervention group. All patients would undergo their supervised post-operative rehabilitation at our institution.

03

Conditions studied

  • Meniscus Disorder
  • Meniscus, Torn Tibial
  • Meniscus Lesion
  • Meniscus Tear, Tibial
  • Atrophy, Muscular

Browse trials for

Keywords

  • blood flow restriction
  • rehabilitation
  • meniscus repair
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who undergo surgery for arthroscopic meniscus repair

Exclusion criteria

Exclusion Criteria:

  • Participants undergoing surgery for concomitant ligamentous surgeries
  • Patients with Diabetes Mellitus, vascular disease, or infections of the involved extremity
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Blood flow restriction

    The blood flow restriction arm will include the use of the pneumatic tourniquet applied to the operative lower extremity throughout post-operative rehabilitation sessions. The tourniquet pressure will be titrated to 80% of the measured extremity arterial limb occlusion pressure with the participant lying supine.

    Device: Blood flow restriction (Delfi Personalized Tourniquet System) · Other: Standard rehabilitation

  • Sham comparator
    Standard rehabilitation

    The standard rehabilitation arm will undergo the same rehabilitation protocol as the experimental arm. A tourniquet will still be applied, but will only be inflated to 20 mmHg, a pressure that will not occlude blood flow.

    Other: Standard rehabilitation

Interventions

  • DeviceBlood flow restriction (Delfi Personalized Tourniquet System)

    The Delfi Personalized Tourniquet System will be utilized to apply the blood flow restriction protocol.

    Also known as: Delfi Personalized Tourniquet System

  • OtherStandard rehabilitation

    Post-operative physical therapy as guided by a standardized protocol for patients undergoing meniscus repair.

06

What researchers measure

Primary outcomes

  1. Knee Extension Force at Week 1

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 1 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  2. Knee Extension Force at Week 2

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 2 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  3. Knee Extension Force at Week 3

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 3 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  4. Knee Extension Force at Week 4

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 4 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  5. Knee Extension Force at Week 5

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 5 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  6. Knee Extension Force at Week 6

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 6 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  7. Knee Extension Force at Week 7

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 7 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  8. Knee Extension Force at Week 8

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 8 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  9. Knee Extension Force at Week 9

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 9 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  10. Knee Extension Force at Week 10

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 10 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  11. Knee Extension Force at Week 11

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 11 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  12. Knee Extension Force at Week 12

    Peak knee extension force (lbs) evaluated with a hand-held dynamometer

    Time frame: Week 12 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  13. Thigh Circumference at Week 1

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 1 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  14. Thigh Circumference at Week 2

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 2 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  15. Thigh Circumference at Week 3

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 3 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  16. Thigh Circumference at Week 4

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 4 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  17. Thigh Circumference at Week 5

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 5 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  18. Thigh Circumference at Week 6

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 6 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  19. Thigh Circumference at Week 7

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 7 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  20. Thigh Circumference at Week 8

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 8 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  21. Thigh Circumference at Week 9

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 9 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  22. Thigh Circumference at Week 10

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 10 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  23. Thigh Circumference at Week 11

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 11 (Evaluated weekly at physical therapy visits from 0-12 weeks)

  24. Thigh Circumference at Week 12

    Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

    Time frame: Week 12 (Evaluated weekly at physical therapy visits from 0-12 weeks)

Secondary outcomes

  1. International Knee Documentation Committee (IKDC) Score at Week 6

    Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms

    Time frame: 6 weeks (measured at 6 weeks, 3 months, and 6 months post-operatively)

  2. International Knee Documentation Committee (IKDC) Score at Week 12

    Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms

    Time frame: 3 months (measured at 6 weeks, 3 months, and 6 months post-operatively)

  3. International Knee Documentation Committee (IKDC) Score at Week 24

    Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms

    Time frame: 6 months (measured at 6 weeks, 3 months, and 6 months post-operatively)

  4. Y-balance Testing at Week 12

    Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.

    Time frame: 3 months (performed at 3 months and 6 months post-operatively)

  5. Y-balance Testing at Week 24

    Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.

    Time frame: 6 months (performed at 3 months and 6 months post-operatively)

  6. 3-hop Test at Week 12

    Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in centimeters. The test is compared to the contralateral, uninjured limb, and scoring is reported as a percentage of the uninjured limb.

    Time frame: 3 months (performed at 3 months and 6 months post-operatively)

  7. 3-hop Test at Week 24

    Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in meters.

    Time frame: 6 months (performed at 3 months and 6 months post-operatively)

  8. Single Leg Squat Testing at Week 12

    Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control

    Time frame: 3 months (performed at 3 months and 6 months post-operatively)

  9. Single Leg Squat Testing at Week 24

    Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control

    Time frame: 6 months (performed at 3 months and 6 months post-operatively)

07

Results

Posted Feb 20, 2026
Limitations and caveats
We had a difficult time enrolling subjects. Subjects could be included if they had an isolated meniscus tear and were doing physical therapy at our university-based PT practice. Many of our patients had associated injuries (ACL tear, etc) that were disqualifying. We excluded meniscus root tears or radial tears that required different rehab plans. We are a tertiary/quaternary referral center and many patients live farther away, so in-person PT was not possible at our location.

Participant flow

Participant flow — Overall Study
MilestoneBlood Flow Restriction GroupControl Group
Started78
Completed78
Not completed00

Outcome measures

PrimaryKnee Extension Force at Week 1

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 1 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 1
lbsBlood Flow Restriction GroupControl Group
Involved Limb36.9 ± 30.321.0 ± 11.1
Contralateral Limb87.1 ± 42.495.6 ± 54.7
PrimaryKnee Extension Force at Week 2

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 2 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 2
lbsBlood Flow Restriction GroupControl Group
Involved Limb38.9 ± 29.833.7 ± 7.4
Contralateral Limb93.0 ± 39.270.2 ± 34.8
PrimaryKnee Extension Force at Week 3

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 3 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 3
lbsBlood Flow Restriction GroupControl Group
Involved Limb45.3 ± 34.329.6 ± 6.3
Contralateral Limb110.3 ± 32.976.2 ± 51.2
PrimaryKnee Extension Force at Week 4

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 4 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 4
lbsBlood Flow Restriction GroupControl Group
Involved limb48.0 ± 39.128.9 ± 4.0
Contralateral limb112.1 ± 27.991.5 ± 34.0
PrimaryKnee Extension Force at Week 5

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 5 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 5
lbsBlood Flow Restriction GroupControl Group
Involved limb49.7 ± 36.529.7 ± 7.3
Contralateral limb117.8 ± 19.496.5 ± 37.5
PrimaryKnee Extension Force at Week 6

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 6 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 6
lbsBlood Flow Restriction GroupControl Group
Involved limb62.3 ± 47.046.0 ± 18.8
Contralateral limb118.8 ± 26.3101.6 ± 33.2
PrimaryKnee Extension Force at Week 7

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 7 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 7
lbsBlood Flow Restriction GroupControl Group
Involved limb64.9 ± 48.155.8 ± 16.6
Contralateral limb121.5 ± 25.398.5 ± 35.8
PrimaryKnee Extension Force at Week 8

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 8 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 8
lbsBlood Flow Restriction GroupControl Group
Involved limb77.7 ± 45.561.2 ± 31.4
Contralateral limb122.1 ± 23.8105.8 ± 51.0
PrimaryKnee Extension Force at Week 9

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 9 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 9
lbsBlood Flow Restriction GroupControl Group
Involved limb82.3 ± 49.565.1 ± 21.0
Contralateral limb119.6 ± 40.0111.0 ± 40.2
PrimaryKnee Extension Force at Week 10

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 10 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 10
lbsBlood Flow Restriction GroupControl Group
Involved limb83.1 ± 45.957.0 ± 10.4
Contralateral limb118.4 ± 42.980.0 ± 31.2
PrimaryKnee Extension Force at Week 11

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 11 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 11
lbsBlood Flow Restriction GroupControl Group
Involved limb81.2 ± 33.341.8 ± 3.5
Contralateral limb112.6 ± 28.392.8 ± 39.1
PrimaryKnee Extension Force at Week 12

Peak knee extension force (lbs) evaluated with a hand-held dynamometer

Time frame:
Week 12 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · lbs
Knee Extension Force at Week 12
lbsBlood Flow Restriction GroupControl Group
Involved limb96.1 ± 40.456 ± 13.2
Contralateral limb126.3 ± 33.2100.8 ± 21.8
PrimaryThigh Circumference at Week 1

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 1 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 1
CentimetersBlood Flow Restriction GroupControl Group
Involved limb42.9 ± 3.643.0 ± 5.8
Contralateral limb43.4 ± 3.244.3 ± 6.4
PrimaryThigh Circumference at Week 2

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 2 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 2
CentimetersBlood Flow Restriction GroupControl Group
Involved limb43.5 ± 4.037.7
Contralateral limb43.7 ± 3.739.6
PrimaryThigh Circumference at Week 3

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 3 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 3
CentimetersBlood Flow Restriction GroupControl Group
Involved limb43.3 ± 3.736.9
Contralateral limb44.1 ± 3.639.6
PrimaryThigh Circumference at Week 4

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 4 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 4
CentimetersBlood Flow Restriction GroupControl Group
Involved limb43.2 ± 3.537
Contralateral limb44.0 ± 3.337.6
PrimaryThigh Circumference at Week 5

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 5 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 5
CentimetersBlood Flow Restriction GroupControl Group
Involved limb43.1 ± 3.736.85 ± 0.07
Contralateral limb44.3 ± 4.037.9 ± 0.4
PrimaryThigh Circumference at Week 6

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 6 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 6
CentimetersBlood Flow Restriction GroupControl Group
Involved limb44.9 ± 4.642.1 ± 5.2
Contralateral limb44.9 ± 4.644.1 ± 6.1
PrimaryThigh Circumference at Week 7

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 7 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 7
CentimetersBlood Flow Restriction GroupControl Group
Involved limb43.2 ± 4.543.5 ± 5.1
Contralateral limb44.4 ± 3.744.1 ± 6.4
PrimaryThigh Circumference at Week 8

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 8 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 8
CentimetersBlood Flow Restriction GroupControl Group
Involved limb44.8 ± 4.637.5
Contralateral limb45.6 ± 3.537.6
PrimaryThigh Circumference at Week 9

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 9 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 9
CentimetersBlood Flow Restriction GroupControl Group
Involved limb44.0 ± 3.937.5
Contralateral limb45.0 ± 3.238.0
PrimaryThigh Circumference at Week 10

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 10 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 10
CentimetersBlood Flow Restriction GroupControl Group
Involved limb43.8 ± 3.437.9
Contralateral limb45.1 ± 3.238.0
PrimaryThigh Circumference at Week 11

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 11 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 11
CentimetersBlood Flow Restriction GroupControl Group
Involved limb42.3 ± 3.238.8
Contralateral limb42.7 ± 2.538.0
PrimaryThigh Circumference at Week 12

Measurement of thigh circumference (centimeters) will be performed utilizing tape measures at specified distances along the thigh

Time frame:
Week 12 (Evaluated weekly at physical therapy visits from 0-12 weeks)
Reported as:
Mean · Centimeters
Thigh Circumference at Week 12
CentimetersBlood Flow Restriction GroupControl Group
Involved limb43.3 ± 4.042.7 ± 3.5
Contralateral limb43.9 ± 4.444.7 ± 6.1
SecondaryInternational Knee Documentation Committee (IKDC) Score at Week 6

Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms

Time frame:
6 weeks (measured at 6 weeks, 3 months, and 6 months post-operatively)
Reported as:
Mean · score on a scale
International Knee Documentation Committee (IKDC) Score at Week 6
score on a scaleBlood Flow Restriction GroupControl Group
International Knee Documentation Committee (IKDC) Score at Week 624.7 ± 0.8137.0 ± 3.8
SecondaryInternational Knee Documentation Committee (IKDC) Score at Week 12

Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms

Time frame:
3 months (measured at 6 weeks, 3 months, and 6 months post-operatively)
Reported as:
Mean · score on a scale
International Knee Documentation Committee (IKDC) Score at Week 12
score on a scaleBlood Flow Restriction GroupControl Group
International Knee Documentation Committee (IKDC) Score at Week 1241.4 ± 8.362.8 ± 6.9
SecondaryInternational Knee Documentation Committee (IKDC) Score at Week 24

Patient-reported outcome measure (numerical score) from survey. Min: 0 = lowest level of function/highest level of symptoms. Max: 100 = highest level of function/lowest level of symptoms

Time frame:
6 months (measured at 6 weeks, 3 months, and 6 months post-operatively)
Reported as:
Mean · score on a scale
International Knee Documentation Committee (IKDC) Score at Week 24
score on a scaleBlood Flow Restriction GroupControl Group
International Knee Documentation Committee (IKDC) Score at Week 2475.3 ± 12.259.8 ± 8.3
SecondaryY-balance Testing at Week 12

Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.

Time frame:
3 months (performed at 3 months and 6 months post-operatively)
Reported as:
Mean · Percentage of limb length
Y-balance Testing at Week 12
Percentage of limb lengthBlood Flow Restriction GroupControl Group
Involved limb98.2 ± 6.695.4
Contralateral limb109.1 ± 11.0102.6
SecondaryY-balance Testing at Week 24

Functional outcome measure (numerical score). The lower quarter Y-balance test evaluates dynamic stability and functional symmetry. The subject stands on a single leg and reaches in three directions (anterior, posteromedial, posterolateral) and a composite score is calculated as a percentage: (sum of reach distances in centimeters in each direction) / (3\*limb length) \* 100.

Time frame:
6 months (performed at 3 months and 6 months post-operatively)
Reported as:
Mean · Percentage of limb length
Y-balance Testing at Week 24
Percentage of limb lengthBlood Flow Restriction GroupControl Group
Involved limb92.596.8 ± 2.3
Contralateral limb115.6101.3 ± 3.7
Secondary3-hop Test at Week 12

Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in centimeters. The test is compared to the contralateral, uninjured limb, and scoring is reported as a percentage of the uninjured limb.

Time frame:
3 months (performed at 3 months and 6 months post-operatively)
Reported as:
Count of participants · Participants
3-hop Test at Week 12
ParticipantsBlood Flow Restriction GroupControl Group
3-hop Test at Week 1200
Secondary3-hop Test at Week 24

Functional outcome measure (numerical score). The 3-hop test assesses dynamic stability and limb control. The subject hops three times consecutively forward in a same line and at the final landing, pauses in position while a measurement is made from the starting line to the toe at the end of the final hop in meters.

Time frame:
6 months (performed at 3 months and 6 months post-operatively)
Reported as:
Mean · Meters
3-hop Test at Week 24
MetersBlood Flow Restriction GroupControl Group
Involved limb4.83.3 ± 1.7
Contralateral limb5.73.4 ± 1.7
SecondarySingle Leg Squat Testing at Week 12

Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control

Time frame:
3 months (performed at 3 months and 6 months post-operatively)
Reported as:
Count of participants · Participants
Single Leg Squat Testing at Week 12
ParticipantsBlood Flow Restriction GroupControl Group
Single Leg Squat Testing at Week 1200
SecondarySingle Leg Squat Testing at Week 24

Functional outcome measure (numerical score). Single leg squat testing evaluates core stability and ability to perform functional movement safely. Subjects will be asked to perform a single leg squat and will be evaluated on 5 criteria, with one point for clinician-rated good performance in each (A) maintenance in balance, depth, speed (B) trunk posture (C) pelvic rotation \& tilt (D) Hip adduction or femoral internal rotation (E) knee joint apparent valgus. Min: 0 = poor balance and motor control; Max: 5 = good balance and motor control

Time frame:
6 months (performed at 3 months and 6 months post-operatively)
Reported as:
Count of participants · Participants
Single Leg Squat Testing at Week 24
ParticipantsBlood Flow Restriction GroupControl Group
Single Leg Squat Testing at Week 2400

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blood Flow Restriction Group0/7 (0%)0/7 (0%)0/7 (0%)
Control Group0/8 (0%)0/8 (0%)0/8 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Blood Flow RestrictionStandard RehabilitationTotal
Mean39.6 ± 7.735.4 ± 12.637.3 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)Blood Flow RestrictionStandard RehabilitationTotal
Female224
Male5611
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Blood Flow RestrictionStandard RehabilitationTotal
Count of participants——0
08

Study locations

1 site
  • University of California, San Francisco
    San Francisco, California 94158, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jun 2023, 31 months.

Results were first posted in Feb 2026, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2020
First posted
Jun 18, 2020
StartActual
Oct 20, 2020
Primary completionActual
Jun 8, 2023
CompletionActual
Jun 8, 2023
Results first posted
Feb 20, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04436523
Responsible party
Sponsor
First posted
Jun 18, 2020
Start date
Oct 20, 2020
Primary completion
Jun 8, 2023
Completion
Jun 8, 2023
Results posted
Feb 20, 2026
Last update
Feb 20, 2026

Study contacts

Sachin Allahabadi, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion